Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
ViRTICo-BP
The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
2 other identifiers
observational
88
1 country
1
Brief Summary
The main purpose of this study is to determine whether functional magnetic resonance imaging (fMRI), can distinguish between service members with and without traumatic brain injury (TBI), as well as those with posttraumatic stress disorder (PTSD) who receive either virtual reality exposure therapy (VRET) or PTSD treatment other than exposure therapy. The investigators and other investigators have previously identified changes in function in multiple regions of the brain in combat veterans with PTSD, and the investigators have also seen that structural changes in the white matter associated with combat TBI are also linked with changes in function, and in turn with PTSD symptoms. However, the investigators need to confirm these findings in larger numbers, and also need to discern whether fMRI can distinguish if there is something significantly different about those who have PTSD after TBI vs. those in whom it does not follow a TBI. Finally, the investigators have previously demonstrated that exposure therapy ameliorates the functional changes in the brain induced by PTSD, but the investigators do not know if similar changes occur with other forms of therapy, so the investigators seek to compare the two directly. It is our expectation that the findings will better inform the choice of therapy for service members with combat-related PTSD, with or without TBI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 6, 2013
CompletedFirst Posted
Study publicly available on registry
November 21, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedFebruary 10, 2016
February 1, 2016
November 6, 2013
February 9, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline functional MRI blood-oxygen-level-dependent (BOLD) signal at 3months
Functional MRI: Requires the exposure of subjects to various sensory stimuli while in the scanner, in order to assess the function of specific regions of the brain, by measuring the blood-oxygen-level-dependent (BOLD) signal. The Affective Stroop is a validated series of stimuli for distinguishing between those with PTSD and controls, that entails showing participants a variety of pictures (some neutral and some emotionally charged), and also asks them to distinguish between various number patterns.
baseline and 3months
Secondary Outcomes (4)
Clinician-Administered PTSD Scale (CAPS)
baseline and 3months
PTSD Checklist-Military Version (PCL-M)
baseline and 3months
Defense Veteran's Brain Injury Center (DVBIC)screen
baseline and 3months
CAGE and Alcohol Use Disorders Identification Test (AUDIT)
baseline and 3month
Study Arms (4)
Healthy Veterans
Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
Veterans with history of blast exposure
OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
Veterans with PTSD receiving usual care
OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
Veterans with PTSD receiving Virtual Reality Exposure Therapy
OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled "Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer" ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment
Eligibility Criteria
Combat OIF/OEF Veterans
You may qualify if:
- Over 18 years of age.
- Able to give written informed consent prior to participation in this study.
- Good overall health. Subjects with stable medical problems (e.g., hypertension, hypothyroidism, diabetes mellitus) that are fully under control with treatment will be included.
- Specific criteria according to arm:
- Healthy OIF/OEF veterans who deployed for at least 3 months in support of OIF/OEF who do not have blast exposure (i.e., within 100 feet of a blast, in which the pressure wave knocked them to the ground or caused other physical symptoms, or the vehicle in which they were riding hit an improvised explosive device, jarring them from their seat) or PTSD: PCL-M\<50, negative history of concussion or loss of consciousness.
- OIF/OEF veterans with a history of blast exposure (as defined above) who do not meet criteria for PTSD (PCL-M \<50)
- OIF/OEF veterans with PTSD only who receive usual care: any form of individual or group psychotherapy so long as it does not include exposure therapy, and/or may be on any combination of prescription psychotropic medications; participants in this group may or may not have a history of blast exposure, provided they did not have loss of consciousness of 60 minutes or more or otherwise meet any criteria for moderate or severe TBI.
- OIF/OEF veterans with PTSD that will receive VRET through the WRNMMC IRB approved protocol entitled "Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer": must meet entry criteria for that study; most notably, they must have combat-related PTSD; participants in this group may or may not have a history of blast exposure, provided they did not have loss of consciousness of 60 minutes or more or otherwise meet any criteria for moderate or severe TBI.
- \--
You may not qualify if:
- Dementia or an inability to read or understand written and oral questions for any other reason.
- The presence of a clinically significant or unstable medical disorder (e.g., unstable angina, uncontrolled diabetes mellitus, uncontrolled hypertension, symptomatic liver or kidney disease).
- Meet DSM-IV criteria for alcohol abuse within 1 month prior to screening.
- Meet DSM-IV criteria for alcohol and/or substance dependence within 1 month prior to screening.
- Currently at imminent or high risk for homicide or suicide.
- A current or past history of schizophrenia, schizoaffective disorder, and bipolar disorder. However, those with a comorbid history of other Axis 1 disorders such as major depression, dysthymia, or panic disorder will be included, if there are neither psychotic features nor significant suicidal or homicidal ideation.
- Active pregnancy, actively seeking to become pregnant or being unwilling to use birth control measures if of child-bearing age and sexually active.
- Residual shrapnel fragments retained within the body as a result of blast injury, or any prosthetic ferro-magnetic metal devices within the body that would pose health risks with the use of MRI. Those with MRI-safe surgical devices such as titanium will be permitted.
- History of claustrophobia or inability to tolerate an MRI in the past without use of sedating medicine, as the use of sedating medicine could interfere with interpretation of the fMRI.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Intrepid Center of Excellence / Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
Related Publications (2)
Roy MJ, Francis J, Friedlander J, Banks-Williams L, Lande RG, Taylor P, Blair J, McLellan J, Law W, Tarpley V, Patt I, Yu H, Mallinger A, Difede J, Rizzo A, Rothbaum B. Improvement in cerebral function with treatment of posttraumatic stress disorder. Ann N Y Acad Sci. 2010 Oct;1208:142-9. doi: 10.1111/j.1749-6632.2010.05689.x.
PMID: 20955336RESULTRoy MJ, Costanzo ME, Blair JR, Rizzo AA. Compelling Evidence that Exposure Therapy for PTSD Normalizes Brain Function. Stud Health Technol Inform. 2014;199:61-5.
PMID: 24875691RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael J Roy, MD, MPH, Colonel (Retired)
Uniformed Services University of the Health Sciences
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 6, 2013
First Posted
November 21, 2013
Primary Completion
July 1, 2014
Study Completion
August 1, 2014
Last Updated
February 10, 2016
Record last verified: 2016-02